Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Sunshine BiopharmaSBFMW 34 3-1 Month Momentum % is N/A% as of Sep. 09, 2026. GuruFocus rates SBFMW with a GF Score™ of 34/100. The stock has 4 warning signs investors should review. Among 1,028 Drug Manufacturers companies, Sunshine Biopharma ranks worse than 97.18% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-09), Sunshine Biopharma's 3-1 Month Momentum % is N/A%.
The industry rank for Sunshine Biopharma's 3-1 Month Momentum % or its related term are showing as below:
SBFMW's 3-1 Month Momentum % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 2.745 * Ranked among companies with meaningful 3-1 Month Momentum % only.
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
Sunshine Biopharma 3-1 Month Momentum % Related Terms
SBFMW vs BUDZ, CVSI, LVRLF: 3-1 Month Momentum % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma 3-1 Month Momentum % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's 3-1 Month Momentum % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Biopharma (SBFMW) has a 3-1 Month Momentum % of N/A% as of Sep. 09, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sunshine Biopharma and its competitors. According to the industry distribution chart, Sunshine Biopharma ranks #999 out of 1028 companies in the Drug Manufacturers industry, placing it in the top 97.2%.
Is Sunshine Biopharma's 3-1 Month Momentum % too high?
Sunshine Biopharma's current 3-1 Month Momentum % is N/A%. Based on the distribution chart, Sunshine Biopharma ranks #999 out of 1028 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Sunshine Biopharma has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's 3-1 Month Momentum % compare to BUDZ and CVSI?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #999 out of 1028 companies for 3-1 Month Momentum %. This places Sunshine Biopharma in the lower half of its industry. The industry median 3-1 Month Momentum % is 2.75. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Drug Manufacturers company?
The median 3-1 Month Momentum % among Drug Manufacturers companies is 2.75, based on 1,028 companies in the industry. Companies in the top quartile (top 25%) have a 3-1 Month Momentum % significantly above this median, while those in the bottom quartile fall well below. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on Sunshine Biopharma and its competitors. For the Drug Manufacturers industry, the median 3-1 Month Momentum % is 2.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Biopharma's current 3-1 Month Momentum % is N/A%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Sunshine Biopharma (SBFMW) has a current 3-1 Month Momentum % of N/A%. The current 3-1 Month Momentum % is N/A%. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For Sunshine Biopharma (SBFMW), the current 3-1 Month Momentum % is N/A% as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFMW
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFMW has been successfully added to your 
